Celldex Therapeutics Other Current Liab Over Time

CLDX Stock  USD 27.44  0.45  1.61%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Celldex Therapeutics Performance and Celldex Therapeutics Correlation.
For more information on how to buy Celldex Stock please use our How to Invest in Celldex Therapeutics guide.
  
Other Current Liabilities is likely to rise to about 25.6 M in 2024.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Celldex Therapeutics. If investors know Celldex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Celldex Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.58)
Revenue Per Share
0.164
Quarterly Revenue Growth
1.103
Return On Assets
(0.20)
Return On Equity
(0.30)
The market value of Celldex Therapeutics is measured differently than its book value, which is the value of Celldex that is recorded on the company's balance sheet. Investors also form their own opinion of Celldex Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Celldex Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Celldex Therapeutics' market value can be influenced by many factors that don't directly affect Celldex Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Celldex Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Celldex Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Celldex Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Other Current Liab Analysis

Compare Celldex Therapeutics and related stocks such as Ideaya Biosciences, AnaptysBio, and MeiraGTx Holdings PLC Other Current Liab Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
201020112012201320142015201620172018201920202021202220232024
IDYA1.8 M1.8 M1.8 M1.8 M1.8 M1.8 M1.8 M1.8 MM63 KM17.3 M25 M17 M11.3 M
ANAB743 K743 K743 K743 K1.1 M2.9 M100017 K58 K871 K15.3 M11.3 M20 M29.2 M30.6 M
MGTX4.6 M4.6 M4.6 M4.6 M4.6 M4.6 M4.6 M2.7 M437.1 K18.1 M44.4 M24.2 M42.6 M43.9 M24.9 M
KROS802 K802 K802 K802 K802 K802 K802 K802 K802 K107 KM6.4 M12.2 M17.9 M18.8 M
RNA11.5 M11.5 M12.5 M9.6 M305 K305 K305 K305 K305 K1.3 M10.9 M28 M60.9 M36.2 M20.9 M
RVMD4.2 M4.2 M4.2 M4.2 M4.2 M4.2 M4.2 M4.2 M8.3 M14.4 M18.8 M21.5 M22.7 M67.3 M70.7 M
DAWNMMMMMMMMMM1.6 M6.5 M15.5 M26.1 M27.4 M
SWTX7.6 M370 K370 K370 K370 K370 K370 K370 K2.9 M9.3 M13.5 M24.2 M38.8 M64.5 M67.7 M
CYTK2.2 M3.2 M4.9 M12 M6.8 M10.8 M18.5 M22.9 M66 K1.1 M17.6 M21 M33.3 M35.3 M37.1 M
EWTX465 K465 K465 K465 K465 K465 K465 K465 K465 K465 K2.8 M6.7 M9.3 M10.8 M6.6 M
DYN611 M135 M111 M279 M414 M408 M378 M570 M193 K1.1 M7.5 M16.9 M13.6 M18.7 M17.8 M
CRNX501 K501 K501 K501 K501 K501 K501 K494 K6.5 M2.8 MM12.6 M17.5 M31.2 M32.7 M
ALXO1.2 M1.2 M1.2 M1.2 M1.2 M1.2 M1.2 M1.2 M1.2 M1.2 MM10.8 M19.2 M25.8 M27.1 M
IMTX21.8 M21.8 M21.8 M21.8 M21.8 M21.8 M21.8 M21.8 M21.8 M3.4 M8.4 M37.3 M27.6 M38 M25 M
BCAB7.1 M7.1 M7.1 M7.1 M7.1 M7.1 M7.1 M7.1 M7.1 M10.5 M10 M15.9 M15.9 M21.3 M14.8 M
AVTE115 K115 K115 K115 K115 K115 K115 K115 K115 K115 K1.2 M958 K4.4 M14.4 M15.1 M
TVTX28.9 K41.2 K1.4 M31.7 M31 M78.2 M75.7 M66.7 M25.5 M68.8 M80.5 M84.9 M104 M119.3 M60.3 M
VTYX269 K269 K269 K269 K269 K269 K269 K269 K269 K269 K301 K7.6 M9.1 M15.5 M16.3 M
COGT118 K118 K118 K118 K118 K118 K118 K180 K1.7 M7.1 M8.3 M8.9 M18.2 M24.7 M26 M

Celldex Therapeutics and related stocks such as Ideaya Biosciences, AnaptysBio, and MeiraGTx Holdings PLC Other Current Liab description

My Equities

My Current Equities and Potential Positions

Celldex Therapeutics
CLDX
ClassificationCancer Fighters
LocationNew Jersey; U.S.A
ExchangeNASDAQ Exchange
USD 27.44

Additional Tools for Celldex Stock Analysis

When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.